EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

Programmed cell death (PD)-1/PD-1 ligand-1 (PD-L1)-targeted therapy has emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK regulates PD-L1 expression in lung cancer remains unknown. A total of 532 pulmonary adenocarcinomas (pADCs), including 58 ALK-translocated tu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Koh, Jaemoon, Jang, Ji-Young, Keam, Bhumsuk, Kim, Sehui, Kim, Moon-Young, Go, Heounjeong, Kim, Tae Min, Kim, Dong-Wan, Kim, Chul-Woo, Jeon, Yoon Kyung, Chung, Doo Hyun
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839370/
https://ncbi.nlm.nih.gov/pubmed/27141364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1108514
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars